SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales moved up 40.39% to Rs. 3638.47 millions for the March 2022 quarter as compared to Rs. 2591.65 millions during the year-ago period.The Net Profit of the company vaulted to 248.27% to Rs. 2244.64  millions from Rs. 644.51 millions in the previous quarter.Operating profit for the quarter ended March 2022 rose to 2919.64 millions as compared to 969.90 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 3638.47 2591.65 40.39 13202.22 10097.19 30.75 13202.22 10097.19 30.75
Other Income 1343.96 32.98 3975.08 1877.88 142.37 1219.01 1877.88 142.37 1219.01
PBIDT 2919.64 969.90 201.02 7677.76 4547.59 68.83 7677.76 4547.59 68.83
Interest 21.89 18.70 17.06 62.31 91.44 -31.86 62.31 91.44 -31.86
PBDT 2897.75 951.20 204.64 7615.45 4456.15 70.90 7615.45 4456.15 70.90
Depreciation 104.21 83.15 25.33 390.97 316.36 23.58 390.97 316.36 23.58
PBT 2793.54 868.05 221.82 7224.48 4139.79 74.51 7224.48 4139.79 74.51
TAX 548.90 223.54 145.55 1643.49 1053.32 56.03 1643.49 1053.32 56.03
Deferred Tax 34.10 40.07 -14.90 67.19 36.17 85.76 67.19 36.17 85.76
PAT 2244.64 644.51 248.27 5580.99 3086.47 80.82 5580.99 3086.47 80.82
Equity 254.57 254.57 0.00 254.57 254.57 0.00 254.57 254.57 0.00
PBIDTM(%) 80.24 37.42 114.42 58.16 45.04 29.12 58.16 45.04 29.12

Cohance Lifesciences Share Price

389.70 26.45 (7.28%)
17-Apr-2026 12:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.00
Dr. Reddys Lab 1230.85
Cipla 1239.45
Zydus Lifesciences 944.70
Lupin 2310.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×